I’m starting something here that doesn’t exist yet: a quarterly market intelligence briefing on the autism business space.
For the past decade, I’ve worked with growth-stage and PE-backed companies operating in behavioral health. I’ve watched this space evolve—watched the market data get better, the investment activity accelerate, the reimbursement environment shift. And I’ve noticed something: there’s a huge gap. Nobody publishes consistent, accessible market analysis on autism investment trends, VC activity, M&A patterns, or reimbursement shifts.
Investors are flying blind. Operators are making decisions on outdated information. VCs are missing signals.
So I’m closing that gap. This is the first edition of a quarterly market roundup covering autism investment trends, funding activity, diagnostics breakthroughs, and reimbursement policy. Every quarter, same time, same format. You’ll know what’s actually happening in this space.
Let’s start with Q1 2026.
The Big Picture — Market Size and Growth
The autism services and diagnostics market is not small. It’s real, it’s growing, and it’s accelerating.
Applied Behavior Analysis (ABA) therapy — the gold standard treatment — is a $8.33B market in 2026. That’s growing at 4.51% annually, which projects to $10.39B by 2031. For context, that’s faster than healthcare inflation and faster than most service-based industries.
Autism diagnostics are a separate, faster-growing segment. The market was $3.84B in 2024 and is projected to hit $9.50B by 2033—an 11.9% compound annual growth rate. That’s nearly triple the growth rate of ABA. Why? Because diagnosis is the bottleneck. Median wait times for developmental pediatrician appointments are 6-12 months in most markets. Technology is starting to bridge that gap.
Both of these sit within a much larger behavioral healthcare market valued at $1 trillion globally. That’s not niche. That’s a major segment of healthcare spending.
The growth drivers are straightforward:
- Prevalence is rising — current estimates put autism diagnosis at 1 in 36 children (CDC, 2024), up from 1 in 150 fifteen years ago.
- Earlier intervention is being mandated — more states require insurance coverage for early intervention. Earlier intervention means better outcomes and higher willingness to pay.
- Workforce gaps are pushing automation — there aren’t enough behavior analysts, speech therapists, or developmental specialists to meet demand. Technology fills that gap.
This is capital-friendly market fundamentals. Large addressable market, secular growth tailwinds, structural supply constraints.
M&A Activity This Quarter
Behavioral health M&A is on pace to smash 2024 records.
Through 2025, there were 75 behavioral health M&A transactions, a 47.1% increase year-over-year. That’s not a fluke. That’s momentum.
What’s interesting is who’s buying.
Strategic acquirers — health systems, large PE-backed operators, and insurance/pharmacy companies — are up 105% in deal count. CVS/Aetna, United Health/Optum, and regional health systems are aggressively consolidating behavioral health providers. They’re not buying for quick flips. They’re buying to build integrated platforms. They need the revenue, the patient relationships, and the data.
Financial buyers (PE firms, growth equity) are up 9.7%. That’s growth, but it’s modest compared to strategics. The reason: multiples are high and strategic acquirers are willing to pay premium prices. When strategics are competing hard, pure-play financial buyers struggle to underwrite returns.
Valuations for ABA providers are holding in the 6-8x EBITDA range. That’s up from 5-6x two years ago. Profitable, growing ABA platforms with diversified payor mixes are seeing the higher end of that range.
Notable activity includes consolidation among mid-market ABA providers, bolt-on acquisitions by larger platforms, and strategic moves by health systems to internalize autism service lines. What we’re not seeing: distressed sales or multiple compression. The market is hot.
VC and Growth Investment
Venture capital is not the primary funding source for autism services — that’s mostly PE and strategic M&A. But the early-stage and tech-enabled spaces are showing interesting patterns.
The Autism Impact Fund has become the flagship vehicle in this space. Launched with $60M under management, it currently has 16 portfolio companies across diagnostics, therapy optimization, school services, employment, and family support. It’s the signal that institutional capital sees this space as durable and scalable.
Recent follow-on funding rounds show investor confidence:
- Cortica (a digital platform for autism diagnosis) received follow-on funding from CVS, Deerfield, and Optum—three major strategics. That’s not typical VC behavior. That’s strategics making bets on who they want to eventually acquire.
- Healios (virtual therapy platform) closed a $15.8M Series B. They’re operating in the highly regulated telehealth space and still getting funded. That tells you about investor appetite.
What’s driving VC interest:
- Software margins are better than services margins. Diagnostics, therapy optimization platforms, and clinical support tools have higher gross margins and better unit economics than ABA service delivery.
- Regulatory barriers are stabilizing. FDA cleared its first autism diagnostic tool in June 2023. There’s now a regulatory pathway. That creates clarity for investors.
- Strategic acquirers have clear M&A playbooks. If you can show a path to acquisition by CVS, Optum, or a large health system, VCs will back you.
The VC thesis is software-enabled autism services, not pure service delivery.
Diagnostics and Technology — The Inflection Point
Here’s where the real innovation is happening.
For 50 years, autism diagnosis required a specialist observation—developmental pediatrician, child psychologist, or neurologist. That created a massive bottleneck. Average wait times exceeded 6 months in most metro areas.
FDA-cleared eye-tracking is the first scalable alternative. EarliPoint Health’s solution (which I work with) achieved FDA clearance in June 2023 for objective autism risk assessment. The performance metrics are compelling:
- 78% sensitivity, 85.4% specificity — that’s clinically meaningful. Not perfect, but good enough to support diagnostic decision-making and rule out false positives.
SenseToKnow’s platform offers similar performance:
- 87.8% sensitivity, 80.8% specificity — slightly different tradeoff. Higher sensitivity (catches more cases) at the cost of specificity.
What this means in practice: a child can get screened in a pediatrician’s office, school, or telehealth visit. No 6-month wait. No travel to a specialist. Risk assessment in 10 minutes.
The market implications are massive:
- Diagnostic backlog clears. Thousands of kids currently waiting for diagnosis can get screened via technology.
- Early intervention rates spike. Earlier diagnosis means earlier intervention, which means better outcomes and higher lifetime value to service providers.
- New payor models emerge. If diagnosis happens in primary care, insurance companies can reimburse screening differently. That creates new market segments.
AI-powered behavioral screening tools are progressing alongside eye-tracking. These aren’t replacement diagnostics yet, but they’re getting better at flagging high-risk cases for specialist evaluation. That triage function alone saves the system money.
The regulatory picture is clearing, too. The FDA has published guidance on software-based diagnostic tools. There’s now a pathway from startup to cleared device. That creates venture-fundable opportunities.
Reimbursement and Policy Watch
This is where the money actually flows.
State Medicaid programs are aggressively expanding autism coverage. Here’s the proof:
North Carolina Medicaid payments for autism-related services grew from $122M (FY2022) to $639M (FY2026) — a 423% increase in four years. That’s not inflation. That’s intentional policy expansion.
Why is this happening?
- Insurance mandates at the state level. Most states now mandate private insurance coverage for autism services. Medicaid follows. Coverage expands reimbursement rates and breadth of covered services.
- Value-based care is shifting incentives. Health systems and insurers are moving toward value-based models where early diagnosis and early intervention improve outcomes and reduce downstream costs. That rewards the diagnostic and early-treatment players.
- Autism is becoming a public health priority. States are treating early identification and intervention as preventive investment, not optional service.
What’s next on the reimbursement front:
- Telehealth carve-outs for autism screening. Several states are considering specific reimbursement codes for technology-enabled screening. That’s a new market.
- Outcome-based contracts. Health plans are experimenting with paying for outcomes (school performance, functional independence) rather than just service hours. That favors operators with data and proven outcomes.
- Medicaid managed care utilization. As Medicaid shifts to managed care (already 60%+ in most states), autism services consolidation will accelerate. Managed care plans want integrated platforms, not fragmented providers.
The reimbursement environment is moving in the right direction—toward broader coverage, higher rates, and better incentive alignment with outcomes.
What to Watch Next Quarter
Three things will shape Q2 and beyond.
1. Autism Investor Summit (May 13-15, Scottsdale)
This is the industry conference now. It draws institutional investors, strategic acquirers, operators, and entrepreneurs. Watch for announcements on funding rounds, M&A activity, and new product launches. If something is happening in autism business, it gets announced here.
2. Additional FDA Clearances for Diagnostic Tools
We’ll likely see one or two more eye-tracking or AI-based diagnostic tools clear FDA review in 2026. Each clearance legitimizes the category and creates new competitive dynamics. Watch for which strategics start acquiring cleared-device companies.
3. State Medicaid Rate Expansions
New York, California, Texas, and several other large states are reviewing autism service reimbursement rates. If any increase rates significantly, it cascades—other states follow. That can shift unit economics across the sector.
4. Consolidation Acceleration
With valuations high and strategic interest intense, we’ll see larger platforms acquire smaller regional players. Watch for 10-15 significant ABA provider acquisitions in the next six months. That’s on the historical trend.
The Bottom Line
Here’s what I’m seeing:
For operators: The market is expanding—more demand, better reimbursement, strategic interest from major acquirers. If you’re running an autism service business, you’re operating in a favorable environment. The challenge is talent and scaling. Focus there.
For investors: This is a durable growth market with clear exit paths. Strategic acquirers are actively buying. Valuations are high but justified by growth and margin expansion. The opportunity is in platforms (consolidated service delivery or software) not single-site operators. And the second wave—diagnostics, data, outcomes measurement—is just starting.
For entrepreneurs: There’s opportunity in the gap between demand and supply. The biggest gaps: workforce tools (training, retention, quality assurance), diagnostic accessibility (telehealth screening, AI triage), and outcome measurement (data platforms that prove value to payors).
This is a first edition. Next quarter, I’ll do this again—same format, fresh data, new trends, updated deal activity. If you’re tracking this space, I’d suggest subscribing or following along. The market is moving fast, and good data is rare.
Note: This is the first edition of a recurring quarterly market roundup on autism business and investment trends. Every quarter, I’ll update the deal activity, funding trends, regulatory developments, and reimbursement changes shaping this space. If you want the next edition delivered directly, subscribe to the Glenmont Consulting blog or follow me on LinkedIn.
